Selexis CHO Cells in Suspension-1

Calendar

 

2021: Upcoming Events

 

Antibody Engineering & Therapeutics EU, Netherlands | June 8 – 10, 2021

BioKorea, Seoul | June 9 – 11, 2021

BIO International Convention US, Boston, USA | June 10 – 11, 2021

BIO Asia Taiwan, Taiwan| July 21 – 25, 2021

Swiss Biotech Day, Basel, Switzerland | September 7 – 7, 2021

BioProcess International Conference & Exhibition (BPI - Boston), Boston Convention Center, USA | September 20 – 23, 2021

Bispecific World Summit | September 22 – 24, 2021

BioJapan, Yokohama, Japan | October 13 – 15, 2021

BioEurope Fall, EMEA | October 25 – 28, 2021

PEGS Europe 2021 (Protein & Antibody Engineering Summit) , Barcelona, Spain | November 2 – 4, 2021

Festival of Biologics - European, Basel, Switzerland | November 9 – 11, 2021

BDP China, China | November 15 – 17, 2021

BioProcess International (BPI) Europe, Viena, Austria | December 1 – 2, 2021

BioPharma Expo (Interphex Japan), Japan| December 8 – 10, 2021

Antibody Engineering & Theraputics (US), USA | December 13 – 17, 2021

BIOFIT , Strasbourg, France | December 14 – 15, 2021

 

Past Events

 

BIO Partnering at JPM, USA | January 11- January 15, 2021

PEPTALK 2021, San Diego, USA | January 19 – January 21, 2021

Swiss Nordic Bio | February 10 – 11 February, 2021

BIO-Europe SPRING, Spain, EMEA | March 22 – 25 March, 2021

Bioprocess International (BPI) West, USA | March 29 – 31 March, 2021

Nordic Life Science Partnering, EMEA | April 20 – 23 April, 2021

Biotechgate Digital Partnering | May 03 – May 07, 2021

PEGS US Boston, USA | May 11 – May 13, 2021
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bi-specific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis-Website-Test-Image-Container 1

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.

Learn More
Selexis-Website-Test-Image-Container 2

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis-Website-Test-Image-Container 3

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 140 drug products in clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

Latest News

June 29, 2021

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Read More
June 1, 2021

Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

Read More

Copyright© 2021 Selexis SA. All Rights Reserved.